Sanjay Chanda
CIK: 0001571820
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AN2 Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
41.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
66K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
66K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
58K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
58K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
41.7K shares- - Feb 20, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)Direct38K shares- - Jan 6, 2026ANTX
AN2 Therapeutics, Inc.
Sale(S)Direct6K shares at avg. $1.01$6K - Jan 5, 2026ANTX
AN2 Therapeutics, Inc.
Sale(S)Direct3.3K shares at avg. $1.00$3K - Feb 26, 2025ANTX
AN2 Therapeutics, Inc.
Award(A)Direct50.3K shares- - Jan 3, 2025ANTX
AN2 Therapeutics, Inc.
Sale(S)Direct3K shares at avg. $1.34$4K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 41,665 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 66,000 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 66,000 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 57,950 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 57,950 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 41,665 | - | - | Direct |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) | 38,000 | - | $0 | Direct |
| Jan 6, 2026 | ANTX AN2 Therapeutics, Inc. | Sale(S) | 5,956 | $1.01 | $6,027 | Direct |
| Jan 5, 2026 | ANTX AN2 Therapeutics, Inc. | Sale(S) | 3,295 | $1.00 | $3,305 | Direct |
| Feb 26, 2025 | ANTX AN2 Therapeutics, Inc. | Award(A) | 50,250 | - | - | Direct |
| Jan 3, 2025 | ANTX AN2 Therapeutics, Inc. | Sale(S) | 2,957 | $1.34 | $3,965 | Direct |
1-11 of 11 transactions
About Chanda Sanjay
Chanda Sanjay (SEC CIK 0001571820) files insider reports with the SEC as Chief Development Officer of AN2 Therapeutics, Inc. (ANTX).
Signal8 holds 5 ownership filings by Chanda Sanjay, all Form 4s, filed between Jan 7, 2025 and Mar 23, 2026. Those filings report 11 transactions, from Jan 3, 2025 to Mar 19, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Chanda Sanjay's filings is in MENLO PARK, CA.
Recent filings by Chanda Sanjay
- Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).
- Mar 19, 2026: Grant or award of ANTX derivative securities (Form 4, code A).
- Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).
- Mar 19, 2026: Grant or award of ANTX derivative securities (Form 4, code A).
- Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).
Other insiders filing for AN2 Therapeutics, Inc. (ANTX)
- Marks Gilbert Lynn, Director
- Martin Patricia A., Director
- Aziz Kabeer, Director
- Trenor Cameron C. III, Chief Medical Officer
- Readnour Robin Shane, Director
- Williams Sarah Joanne, Principal Accounting Officer